Amgen, a pioneer in biotechnology, harnesses the power of cellular and molecular biology and medicinal chemistry to discover, develop and deliver innovative human therapeutics. For more than 25 years, Amgen science has generated important medical discoveries, resulting in medicines that have helped millions of patients fight cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.
Scientific innovation is our heritage and our future. With a deep and broad pipeline of potential new therapeutic candidates, and active research programs in oncology, inflammation, metabolic and bone disorders, hematology, nephrology, and neuroscience, we are dedicated to advancing science to help patients. That dedication shows in our interdisciplinary and modality-independent approach to research and development. Amgen scientists first identify a disease target and then select the best modality - protein, small molecule, or antibody - to interact with that target to block the disease process.
To fully realize the promise of biotechnology to dramatically improve people's lives, we extend science beyond the lab and clinic, into the production plant. Amgen is recognized worldwide for unparalleled expertise in the complex field of biologics manufacturing. We currently produce more than a third of the world's non-vaccine and non-insulin protein therapeutics, and we adhere to the highest standards of quality and consistency to ensure a reliable supply of vital medicines for the many patients who need them.
Originally founded in 1980 as AMGen (Applied Molecular Genetics), Amgen pioneered the development of novel and innovative products based on advances in recombinant DNA and molecular biology. More than a decade ago, Amgen introduced two of the first biologically derived human therapeutics, EPOGEN® (epoetin alfa) and NEUPOGEN® (filgrastim), which became the biotechnology industry's first blockbusters. These products have improved the lives of hundreds of thousands of patients suffering from conditions related to chronic kidney disease and cancer.
Today, Amgen is a Fortune 500 company whose business has expanded to serve patients around the world in supportive cancer care and the treatment of anemia, rheumatoid arthritis, and other autoimmune diseases such as psoriatic arthritis and ankylosing spondylitis. We continue to sustain a culture rooted in biotechnology entrepreneurialism and innovation. As a science-based and patient-focused organization, Amgen will follow the science wherever it may lead, to best treat grievous illness.
Amgen's research and product development programs aim to help patients in the following therapeutic areas: oncology, inflammation, hematology & nephrology, neurology, and metabolic disorders & osteoporosis. Amgen's marketed products include Aranesp® (darbepoetin alfa), ENBREL® (etanercept), EPOGEN® (Epoetin alfa), Kineret® (anakinra), Neulasta® (pegfilgrastim), NEUPOGEN® (Filgrastim) and Sensipar™ (cinacalcet HCl).
Headquartered in Southern California, with offices or subsidiaries in 31 countries, Amgen is traded on the NASDAQ stock exchange under the symbol AMGN. Amgen is committed to our mission to serve patients - a mission that unites our 15,000 staff members around the world. For more information about Amgen, our pioneering science, and our vital medicines, visit www.amgen.com.
